S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
Log in

LivaNova Stock Price, Forecast & Analysis (NASDAQ:LIVN)

$76.62
+0.46 (+0.60 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$74.74
Now: $76.62
$76.94
50-Day Range
$67.35
MA: $73.01
$77.97
52-Week Range
$64.80
Now: $76.62
$126.99
Volume404,700 shs
Average Volume483,532 shs
Market Capitalization$3.71 billion
P/E Ratio24.17
Dividend YieldN/A
Beta0.53
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV”) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LIVN
CUSIPN/A
Phone44-0-20-3325-0660

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.11 billion
Cash Flow$5.15 per share
Book Value$30.89 per share

Profitability

Net Income$-189,400,000.00

Miscellaneous

Employees4,000
Market Cap$3.71 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive LIVN News and Ratings via Email

Sign-up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.


LivaNova (NASDAQ:LIVN) Frequently Asked Questions

What is LivaNova's stock symbol?

LivaNova trades on the NASDAQ under the ticker symbol "LIVN."

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) released its quarterly earnings results on Wednesday, October, 30th. The company reported $0.84 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.75 by $0.09. The business earned $268.60 million during the quarter, compared to analyst estimates of $273.41 million. LivaNova had a negative net margin of 20.35% and a positive return on equity of 9.44%. The business's revenue was down 1.3% on a year-over-year basis. During the same period last year, the business earned $0.78 EPS. View LivaNova's Earnings History.

When is LivaNova's next earnings date?

LivaNova is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for LivaNova.

What guidance has LivaNova issued on next quarter's earnings?

LivaNova updated its FY19 earnings guidance on Wednesday, October, 30th. The company provided EPS guidance of $3.00-3.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.06. The company issued revenue guidance of $1.11-1.14 billion, compared to the consensus revenue estimate of $1.11 billion.

What price target have analysts set for LIVN?

6 brokers have issued 12 month price objectives for LivaNova's stock. Their forecasts range from $88.00 to $114.00. On average, they anticipate LivaNova's share price to reach $99.40 in the next twelve months. This suggests a possible upside of 29.7% from the stock's current price. View Analyst Price Targets for LivaNova.

What is the consensus analysts' recommendation for LivaNova?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for LivaNova.

What are Wall Street analysts saying about LivaNova stock?

Here are some recent quotes from research analysts about LivaNova stock:
  • 1. According to Zacks Investment Research, "LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company's operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. " (10/2/2019)
  • 2. BTIG Research analysts commented, "As expected, LIVN revised down FY19 guidance following the pre- announcement. Although we had taken down estimates following the miss, the cut to the U.S. Neuromod outlook was still $10-20M worse than we expected. FY19 EPS is now expected to reach $3.00-3.10, ~$0.15 lower than our already lowered $3.21 forecast. Comps turn more difficult on the base business but with a fuller impact from Epidiolex going forward and no imminent relief in the lagging Heart valves business, we feel that even meeting the low end of the 1-3% constant currency guidance could prove challenging. Optics should improve in the back half when the TRD trial begins to enroll but even successful enrollment and reimbursement are not entirely certain. Overall, we think it will take a few quarters to regain credibility and enhance investor confidence in a turnaround in FY20." (5/2/2019)
  • 3. Needham & Company LLC analysts commented, "LIVN beat consensus revenue and EPS in 4Q18. Management provided 2019 revenue growth guidance that was above consensus at the mid-point and adjusted EPS guidance that was below consensus due to treatment- resistant depression (TRD) investments (costing $0.15-0.20 of EPS). Organic revenue growth slowed to 7% in 4Q18 from 8% in 3Q18 given a tougher comp and weakness in Cardiovascular, slightly offset by strength in Neuromodulation. Gross margin was up 470 bps Y/Y while operating margin was up 80 bps Y/Y due to SG&A and R&D investments to fund current and future growth initiatives. While we expect LIVN’s reinvestment to weigh on its margins and EPS in the near-term, we believe it will drive faster revenue growth in future periods and we reiterate our Buy rating." (2/27/2019)

Has LivaNova been receiving favorable news coverage?

Headlines about LIVN stock have trended very negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. LivaNova earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for LivaNova.

Are investors shorting LivaNova?

LivaNova saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 1,860,000 shares, a drop of 7.5% from the August 30th total of 2,010,000 shares. Based on an average daily volume of 392,400 shares, the days-to-cover ratio is presently 4.7 days. Currently, 3.9% of the company's stock are sold short. View LivaNova's Current Options Chain.

Who are some of LivaNova's key competitors?

What other stocks do shareholders of LivaNova own?

Who are LivaNova's key executives?

LivaNova's management team includes the folowing people:
  • Mr. Damien McDonald, CEO & Director (Age 54)
  • Mr. Thad Huston, Chief Financial Officer (Age 49)
  • Mr. Douglas J. Manko, Chief Accounting Officer (Age 45)
  • Ms. Keyna Pidcock Skeffington, Gen. Counsel & Sr. VP (Age 56)
  • Mr. David S. Wise, Sr. Advisor (Age 64)

Who are LivaNova's major shareholders?

LivaNova's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Paradice Investment Management LLC (0.97%), Vaughan Nelson Investment Management L.P. (0.71%), Fisher Asset Management LLC (0.51%), Eagle Asset Management Inc. (0.38%), Emerald Advisers LLC (0.38%) and Wedge Capital Management L L P NC (0.35%). Company insiders that own LivaNova stock include Alfred J Novak, Alistair Simpson, Damien Mcdonald, Daniel Jeffrey Moore, David S Wise, Douglas John Manko, Francesco Bianchi, Hugh M Morrison, Thad Allen Huston and William A Kozy. View Institutional Ownership Trends for LivaNova.

Which institutional investors are selling LivaNova stock?

LIVN stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Eagle Asset Management Inc., Vaughan Nelson Investment Management L.P., Zurcher Kantonalbank Zurich Cantonalbank, Comerica Bank, Daiwa Securities Group Inc., SG Americas Securities LLC and Gabelli Funds LLC. Company insiders that have sold LivaNova company stock in the last year include Alfred J Novak, Alistair Simpson, Damien Mcdonald, Daniel Jeffrey Moore, David S Wise and Thad Allen Huston. View Insider Buying and Selling for LivaNova.

Which institutional investors are buying LivaNova stock?

LIVN stock was bought by a variety of institutional investors in the last quarter, including Paradice Investment Management LLC, Waverton Investment Management Ltd, CWM LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Emerald Advisers LLC, State of Tennessee Treasury Department and Emerald Mutual Fund Advisers Trust. View Insider Buying and Selling for LivaNova.

How do I buy shares of LivaNova?

Shares of LIVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is LivaNova's stock price today?

One share of LIVN stock can currently be purchased for approximately $76.62.

How big of a company is LivaNova?

LivaNova has a market capitalization of $3.71 billion and generates $1.11 billion in revenue each year. The company earns $-189,400,000.00 in net income (profit) each year or $3.17 on an earnings per share basis. LivaNova employs 4,000 workers across the globe.View Additional Information About LivaNova.

What is LivaNova's official website?

The official website for LivaNova is http://www.livanova.com/.

How can I contact LivaNova?

LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company can be reached via phone at 44-0-20-3325-0660 or via email at [email protected]


MarketBeat Community Rating for LivaNova (NASDAQ LIVN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  296 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  505
MarketBeat's community ratings are surveys of what our community members think about LivaNova and other stocks. Vote "Outperform" if you believe LIVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel